Oxford BioMedica plc (OXBDF)
OTHER OTC:OXBDF
Holding OXBDF?
Track your performance easily

Oxford BioMedica (OXBDF) Income Statement

57 Followers

Oxford BioMedica Income Statement

Last quarter (Q2 2022), Oxford BioMedica's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, Oxford BioMedica's net income was £―. See Oxford BioMedica’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
-£ 139.99M£ 142.80M£ 87.73M£ 64.06M£ 66.78M
Cost of Revenue
-£ 70.81M£ 60.16M£ 41.66M£ 43.10M£ 34.50M
Gross Profit
-£ 69.18M£ 82.64M£ 46.07M£ 20.96M£ 32.27M
Operating Expense
-£ 123.05M£ 61.71M£ 50.94M£ 33.54M£ 24.34M
Operating Income
-£ -53.87M£ 20.93M£ -4.86M£ -12.58M£ 7.93M
Net Non Operating Interest Income Expense
-£ -7.78M£ 888.00K£ -878.00K£ -5.45M£ -6.16M
Other Income Expense
-£ -23.64M----
Pretax Income
-£ -45.98M£ 19.88M£ -6.57M£ -20.89M£ 5.01M
Tax Provision
-£ -817.00K£ 869.00K£ -327.00K£ -4.82M£ -2.53M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ -39.16M£ 19.01M£ -6.25M£ -16.07M£ 7.54M
Basic EPS
-£ -0.41£ 0.23£ -0.08£ -0.22£ 0.12
Diluted EPS
-£ -0.41£ 0.22£ -0.08£ -0.22£ 0.11
Basic Average Shares
-£ 94.83M£ 83.48M£ 79.94M£ 72.71M£ 65.19M
Diluted Average Shares
-£ 94.83M£ 83.48M£ 79.94M£ 72.71M£ 69.24M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
---£ 173.00K£ 104.00K£ 30.00K
Total Expenses
-£ 193.85M£ -121.86M£ 92.59M£ 76.64M£ 58.85M
Net Income From Continuing And Discontinued Operation
-£ -39.16M£ 19.01M£ -6.25M£ -16.07M£ 7.54M
Normalized Income
-£ -46.79M£ 16.10M£ -5.46M£ -14.62M£ 2.69M
Interest Expense
---£ 912.00K£ 5.56M£ 6.23M
EBIT
-£ -37.22M£ 20.77M£ -5.66M£ -15.33M£ 11.24M
EBITDA
-£ -10.28M£ 20.77M£ 4.18M£ -9.54M£ 15.60M
Currency in GBP

Oxford BioMedica Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis